Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06903715 · ClinicalTrials.gov registry record · Phase 1
A Clinical Study of Belzutifan (MK-6482) Alone or With Phenytoin in Healthy Participants (CA46602/MK-6482-035)
A Phase 1 study, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT06903715 is a Phase 1 study that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 14 participants.
The verdict
NCT06903715, a Phase 1 study, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
Researchers designed belzutifan, the study medicine, to treat certain kinds of cancer. The goal of this study is to learn what happens to belzutifan in a healthy person's body over time when taken, by mouth, as a tablet. Researchers will learn what happens when belzutifan is taken alone and when it is taken after several days of treatment with phenytoin.
Interventions
- DRUG Belzutifan
- DRUG Phenytoin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2025-03-28 |
| Est. Completion | 2025-05-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06903715
The ClinicalTrials.gov registry entry for NCT06903715 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Belzutifan is the first listed.
NCT06903715 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06903715 about?
NCT06903715 is a clinical study titled "A Clinical Study of Belzutifan (MK-6482) Alone or With Phenytoin in Healthy Participants (CA46602/MK-6482-035)". Researchers designed belzutifan, the study medicine, to treat certain kinds of cancer. The goal of this study is to learn what happens to belzutifan in a healthy person's body over time when taken, by mouth, as a tablet. Researchers will learn what happens when belzutifan is taken alone and when it...
What is the current status of trial NCT06903715?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2025-03-28. Estimated completion is 2025-05-27.
What interventions are being tested in trial NCT06903715?
The interventions under investigation include: Belzutifan (DRUG), Phenytoin (DRUG).
Who is sponsoring clinical trial NCT06903715?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.